# Nurtec Odt (rimegepant sulfate) PDUFA date and FDA approval status

Canonical: https://sec-api.dev/pdufa/rimegepant

> The FDA approved Nurtec Odt (rimegepant sulfate), sponsored by PFIZER INC (PFE), on February 27, 2020.

Data as of November 16, 2026 (snapshot 20261116T222116Z). Every date quotes the SEC filing or FDA page it came from. Date precision: exact day, quarter only, month only.

**Free:** every drug page and the next 30 days of the FDA calendar, no account. Calendar API, alerts when a date moves, and full history: https://sec-api.dev/pricing . Free API key: https://sec-api.dev/sign-up?ref=ai-claudebot

## Key facts

| Field | Value |
| --- | --- |
| Drug | Nurtec Odt (rimegepant sulfate) |
| Codes | BHV3000 |
| Sponsor | PFIZER INC (PFE) https://sec-api.dev/companies/pfe/catalysts |
| Indications | [Migraine](https://sec-api.dev/indications/migraine), [Menstrual Migraine](https://sec-api.dev/indications/menstrual-migraine), [Preventive Treatment of Migraine](https://sec-api.dev/indications/preventive-treatment-of-migraine) |
| Modality |  |
| FDA designations | priority review |

## Timeline

### February 27, 2020: FDA approval

- Status: completed, approved. Date confidence: exact.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- openFDA Drugs@FDA: "NDA212728 ORIG-1 (Type 1 - New Molecular Entity): submission_status AP, submission_status_date 20200227, review_priority PRIORITY; sponsor_name PFIZER; product NURTEC ODT (RIMEGEPANT SULFATE)." https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA212728%22

### May 27, 2021: label expansion decision

- Status: completed, approved. Date confidence: exact.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- openFDA Drugs@FDA: "NDA212728 SUPPL-6 (Efficacy): submission_status AP, submission_status_date 20210527, review_priority STANDARD; sponsor_name PFIZER; product NURTEC ODT (RIMEGEPANT SULFATE)." https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA212728%22

### April 11, 2022: label expansion decision

- Status: completed, approved. Date confidence: exact.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- openFDA Drugs@FDA: "NDA212728 SUPPL-9 (Efficacy): submission_status AP, submission_status_date 20220411, review_priority STANDARD; sponsor_name PFIZER; product NURTEC ODT (RIMEGEPANT SULFATE)." https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA212728%22

### August 25, 2025: primary completion

- Status: completed. Date confidence: exact. Stage: 3. Indication: Migraine.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT05810038 (A Study to Learn About the Safety and Effects of Rimegepant to Prevent Migraine in Chinese Subjects.): Overall Status COMPLETED; Phase PHASE3; Primary Completion 2025-08-25 (ACTUAL); Lead Sponsor Pfizer; Results First Posted 2026-09-03." https://clinicaltrials.gov/study/NCT05810038

### September 3, 2026: topline data readout

- Status: completed. Date confidence: exact. Stage: 3. Indication: Migraine.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT05810038 (A Study to Learn About the Safety and Effects of Rimegepant to Prevent Migraine in Chinese Subjects.): Overall Status COMPLETED; Phase PHASE3; Primary Completion 2025-08-25 (ACTUAL); Lead Sponsor Pfizer; Results First Posted 2026-09-03." https://clinicaltrials.gov/study/NCT05810038?tab=results

### Nov 2026 to Feb 2027: topline data readout

- Status: scheduled. Date confidence: quarter. Stage: 3. Indication: Menstrual Migraine.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT06641466 (A Study to Learn About the Study Medicine Called Rimegepant in Women When Used for Intermittent Prevention of Menstrual Migraine): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2026-11-29 (ESTIMATED); Lead Sponsor Pfizer." https://clinicaltrials.gov/study/NCT06641466

### November 2026: primary completion

- Status: scheduled. Date confidence: month. Stage: 3. Indication: Menstrual Migraine.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT06641466 (A Study to Learn About the Study Medicine Called Rimegepant in Women When Used for Intermittent Prevention of Menstrual Migraine): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2026-11-29 (ESTIMATED); Lead Sponsor Pfizer." https://clinicaltrials.gov/study/NCT06641466

### Oct 2028 to Jan 2029: topline data readout

- Status: scheduled. Date confidence: quarter. Stage: 3. Indication: Preventive Treatment of Migraine.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT07729462 (A Study to Learn About the Study Medicine Called Rimegepant in Adults When Used for the Prevention of Chronic Migraine): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2028-10-21 (ESTIMATED); Lead Sponsor Pfizer." https://clinicaltrials.gov/study/NCT07729462

### October 2028: primary completion

- Status: scheduled. Date confidence: month. Stage: 3. Indication: Preventive Treatment of Migraine.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT07729462 (A Study to Learn About the Study Medicine Called Rimegepant in Adults When Used for the Prevention of Chronic Migraine): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2028-10-21 (ESTIMATED); Lead Sponsor Pfizer." https://clinicaltrials.gov/study/NCT07729462

### Mar to Jun 2029: topline data readout

- Status: scheduled. Date confidence: quarter. Stage: 3. Indication: Migraine.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT05156398 (Efficacy and Safety Study of Rimegepant for the Preventative Treatment of Migraine in Pediatric Subjects): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2029-03-27 (ESTIMATED); Lead Sponsor Pfizer." https://clinicaltrials.gov/study/NCT05156398

### March 2029: primary completion

- Status: scheduled. Date confidence: month. Stage: 3. Indication: Migraine.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT05156398 (Efficacy and Safety Study of Rimegepant for the Preventative Treatment of Migraine in Pediatric Subjects): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2029-03-27 (ESTIMATED); Lead Sponsor Pfizer." https://clinicaltrials.gov/study/NCT05156398

### Feb to May 2030: topline data readout

- Status: scheduled. Date confidence: quarter. Stage: 3. Indication: Migraine.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT06616194 (A Study to Learn About the Study Medicine Called Rimegepant in Adolescents With Frequent Migraine): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2030-02-26 (ESTIMATED); Lead Sponsor Pfizer." https://clinicaltrials.gov/study/NCT06616194

### February 2030: primary completion

- Status: scheduled. Date confidence: month. Stage: 3. Indication: Migraine.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT06616194 (A Study to Learn About the Study Medicine Called Rimegepant in Adolescents With Frequent Migraine): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2030-02-26 (ESTIMATED); Lead Sponsor Pfizer." https://clinicaltrials.gov/study/NCT06616194

## Same indication

- [Qulipta (atogepant)](https://sec-api.dev/pdufa/atogepant) (ABBV)
- [Erenumab dose 1](https://sec-api.dev/pdufa/erenumab) (AMGN)
- [Evo756, dose 1](https://sec-api.dev/pdufa/evo756) (EVMN)
- [AJOVY® (fremanezumab)](https://sec-api.dev/pdufa/fremanezumab) (TEVA)
- [Reyvow (lasmiditan succinate)](https://sec-api.dev/pdufa/lasmiditan) (LLY)
- [MEDI0618](https://sec-api.dev/pdufa/medi0618) (ABBV)
- [Ubrelvy (ubrogepant)](https://sec-api.dev/pdufa/ubrogepant) (ABBV)
- [Zavzpret ® (zavegepant)](https://sec-api.dev/pdufa/zavegepant) (PFE)

Calendar months: [November 2026](https://sec-api.dev/fda-calendar/2026-11), [October 2028](https://sec-api.dev/fda-calendar/2028-10)

## Feeds and downloads

- Subscribe (iCal): https://sec-api.dev/pdufa/rimegepant.ics
- Next 30 days as CSV: https://sec-api.dev/fda-calendar.csv . JSON: https://sec-api.dev/fda-calendar.json . All events (iCal): https://sec-api.dev/fda-calendar.ics
- New or moved PDUFA dates: https://sec-api.dev/pdufa-dates/feed.xml (RSS), https://sec-api.dev/pdufa-dates/feed.json (JSON Feed)
- FDA approvals: https://sec-api.dev/fda-approvals-today/feed.xml (RSS), https://sec-api.dev/fda-approvals-today/feed.json (JSON Feed)
- License: CC BY 4.0 for the public 30-day window (https://sec-api.dev/biotech/license.txt). Full history: https://sec-api.dev/pricing

## Cite this page

sec-api.dev. "Nurtec Odt (rimegepant sulfate) PDUFA date and FDA approval status." Biotech catalyst calendar, data as of November 16, 2026 (snapshot 20261116T222116Z). https://sec-api.dev/pdufa/rimegepant

```bibtex
@misc{secapidev_pdufa_rimegepant_20261116,
  title        = {Nurtec Odt (rimegepant sulfate) PDUFA date and FDA approval status},
  author       = {{sec-api.dev}},
  year         = {2026},
  month        = {nov},
  howpublished = {\url{https://sec-api.dev/pdufa/rimegepant}},
  note         = {Biotech catalyst calendar, data as of 2026-11-16, snapshot 20261116T222116Z. Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source.}
}
```

```json
{"type":"dataset","id":"secapidev_pdufa_rimegepant_20261116","title":"Nurtec Odt (rimegepant sulfate) PDUFA date and FDA approval status","publisher":"sec-api.dev","URL":"https://sec-api.dev/pdufa/rimegepant","issued":{"date-parts":[[2026,11,16]]},"version":"20261116T222116Z","license":"https://creativecommons.org/licenses/by/4.0/","note":"Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source."}
```

---
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Food and Drug Administration or the U.S. Securities and Exchange Commission. Dates are as stated by sponsors and FDA; the FDA can act before or after a target date. Not investment advice.
